Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

New Alzheimer's Program: Voyager Therapeutics has launched a new program that uses an intravenous-delivered TRACER™ capsid to target and silence the high-risk APOE4 variant while delivering the protective APOE2 variant, aiming to reduce Alzheimer's disease risk in carriers of APOE4.

Expanded Alzheimer’s Franchise: The company's Alzheimer’s disease franchise now includes multiple clinical-stage assets, such as the anti-tau antibody VY7523 and gene therapies targeting tau, amyloid, and APOE, with plans for further data presentations in 2025.